The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression

Yu, Lu‐Gang

doi:10.1007/s10719-007-9034-3

Cited by 167 publications

(166 citation statements)

References 105 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…Another galectin-binding carbohydrate that has been described to facilitate adhesion of cancer cells to the endothelium is the Thomsen-Friendenreich glycoantigen (TFag; recently reviewed by Yu 79 ). High expression of TFag is associated with most human cancers, and at least 2 surface molecules are known to present TFag (ie, CD44v6 and the transmembrane mucin MUC1).…”

Section: Tumor Metastasis Formationmentioning

confidence: 99%

Galectins in the tumor endothelium: opportunities for combined cancer therapy

Thijssen

Poirier

Baum

et al. 2007

Blood

120

View full text Add to dashboard Cite

Galectins are emerging as a family of proteins that play an important role in several steps of tumorigenesis. Evidence is accumulating that galectins are expressed by the tumor endothelium, where they contribute to different steps of tumor progression such as immune escape and metastasis. Recent studies have identified an important role for galectins in tumor angiogenesis. Moreover, it has been shown that galectins in the endothelium can be targeted for therapeutic applications. This opens a window of opportunity for the development of tumor-type independent treatment strategies. This review focuses on the expression of galectins in the tumor endothelium, their contribution to tumor progression, and their application in tumor-type independent cancer therapy.

show abstract

Section: Tumor Metastasis Formationmentioning

confidence: 99%

Galectins in the tumor endothelium: opportunities for combined cancer therapy

Thijssen

Poirier

Baum

et al. 2007

Blood

120

View full text Add to dashboard Cite

show abstract

“…It has been shown previously that in carcinoma cells the incomplete elongation of O-glycan saccharide chains leads to the expression of shorter carbohydrate structures such as Tn, sialyl-Tn, or T antigens, which are usually expressed on MUC1 mucin as their carbohydrate structures [35][36][37]. Thomsen-Friedenreich carbohydrate antigen (Galβ1-3GalNAcα1-Ser/Thr -TF or T antigen), observed on the surface of endothelial cells, could play a role in the interactions of these cells with galectin-3, similarly to cancer cells [38].…”

Section: Discussionmentioning

confidence: 99%

Expression of MUC1 mucin in human umbilical vein endothelial cells (HUVEC).

Porowska

Paszkiewicz-Gadek²,

Wosek³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Mucin 1 (MUC1) is a membrane-bound glycoprotein that is expressed by various epithelial cell types. MUC1 functions include modulation of cell adhesion, signal transduction, lubrication and hydration of epithelial surfaces, and their protection from infection. In this study we demonstrated that MUC1 is expressed in human umbilical vein endothelial cells (HUVECs) and could be released/shed from cellular membrane. MUC1 presence in these cells was verified using three methods: Western blotting, flow cytometry and metabolic labeling. We also showed that mucin expression is stimulated by proinflammatory cytokines: about a 2-fold increase was observed after TNF-α treatment and lower after IFN-γ alone and in combination with TNF-α treatment. It can be assumed that the presence of MUC1 in endothelial cells may have an important role in the interactions with different cell types in physiological and pathological processes.

show abstract

“…It is enormously significant for cancer etiology, pathology, diagnostics and therapeutics [9][10][11]. Similarly, some sia-containing antigens show an important medical significance [21]. In order not to duplicate similar studies, we neglect large literature details.…”

Section: Current Knowledges Towards Sia-related Biologic and Pathogenmentioning

confidence: 99%

Antimetastatic therapy at aberrant sialylation in cancer cells, a potential hotspot

Lu¹,

Lu²,

Xu³

et al. 2017

Clin Proteom Bioinform

View full text Add to dashboard Cite

Neoplasm metastases involve a fixed cascade of pathological processes responsible for 90% cancer mortality worldwide. However, currently neoplasm metastases are poorly managed in humans for lack of good drug targets. To change this situation, new drug targets must be established. Aberrantly tumor sialylated study is one of potential drug targets, which has been involved for a half century. Many new discoveries show promising outcomes in experimental models. Since neoplasm tissues often contain higher levels of total sialic acids (sia), sialic acids-containing antigens, several types of sialic acid analogue, such as N-glycolylneuraminic acids, growing attentions of sia-related tumor diagnostics and therapeutics are needed to work with new cancer treatment approaches. Previously some compounds that inhibit pathologic pathways of sialic acids in tumor movements in vitro and tumor metastasis in animal tumor models were found. This type of pharmacological limitations of cancer metastasis treatments can be possibly solved by future glycome/metabolomics technology utilities. As the "central dogma" of glycobiology is still unknown to us, some fundamental questions related to carbohydrate itself are even more important comparing with individual experimental discoveries. In addition, mathematicor physics-majored talents in this topic might catalyze these new discoveries. In this review, we document these strings of lab biologic evidence, drug development updating and close relationships between cancer pathological profiles and therapeutic targets/benefits in clinics.

show abstract

The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression

Cited by 167 publications

References 105 publications

Galectins in the tumor endothelium: opportunities for combined cancer therapy

Galectins in the tumor endothelium: opportunities for combined cancer therapy

Expression of MUC1 mucin in human umbilical vein endothelial cells (HUVEC).

Antimetastatic therapy at aberrant sialylation in cancer cells, a potential hotspot

Contact Info

Product

Resources

About